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Streptococcus bovis is a Gram-positive bacterium causing serious human infections, including endocarditis and bacteremia, and is
usually associated with underlying disease. The aims of the current study were to compare prevalence of the bacterium associated
with malignant and nonmalignant gastrointestinal diseases and to determine the susceptibility of the isolated strains to diﬀerent
antimicrobial agents. The result showed that the prevalence of S. bovis in stool specimens from patients with malignant or with
nonmalignant gastrointestinal diseases was statistically signiﬁcant. This result may support the idea that there is correlation
between S. bovis and the malignant gastrointestinal diseases.
1.Introduction
Several species of bacteria have been linked to chronic
infections of colon and have been shown to increase the risk
of colon cancer. Streptococcus bovis has been evaluated as one
of the possible etiologic agents for colorectal cancer [1].
S. bovis is a Gram-positive bacterium, which is consid-
ered as a normal inhabitant of the human gastrointestinal
tract but is less frequently present than other Streptococcus
species [2]. Whatever, S. bovis has been shown to be an
increased cause of endocarditis and bacteraemia and found
to be associated with gastrointestinal diseases [3–6]o rw i t h
the colorectal cancer [7–10].
Although a number of bacteria have been associated with
cancer, their possible role in carcinogenesis is unclear. In
some cases Helicobacter pylori may cause stomach cancer
[11, 12] since animal models have demonstrated Koch’s third
andfourthpostulatesfortheroleofH.pyloriinthecausation
of stomach cancer [13]. Moreover, it has been found also
that Salmonella typhi is associated with gallbladder cancer
[14]a n dEscherichia coli with Crohn’s disease as well as colon
cancer [15, 16].
McCoy and Mason ﬁrst reported a case of the association
between streptococcal endocarditis and colon cancer in 1951
[7]. Many studies have examined the presence of S. bovis
in stool samples obtained from patients with colorectal
cancer to ﬁnd a relationship between this bacterium and
the risk of colorectal cancer. In 1977, Klein et al. found a
signiﬁcantly strong association of S. bovis in stool samples
ofpatientswithcoloncancercomparedwithhealthycontrols
andpatientswithnonmalignantgastrointestinaldisease[17].
This important ﬁnding was conﬁrmed in later studies [18–
20]. In contrast, other studies did not ﬁnd any signiﬁcant
association between faecal S. bovis and human colorectal
cancer [21–24].
T h ea i m so ft h ec u r r e n ts t u d yw e r et oi s o l a t eS. bovis
from stool specimens collected from patients with malignant
and non-malignant gastrointestinal diseases and from a
healthy group to compare the association of the bacterium
in malignant and non-malignant gastrointestinal diseases
and to determine the susceptibility of the isolated strains to
diﬀerent antimicrobial agents.
2.MaterialsandMethods
2.1. Study Area and Population. Stool specimens were col-
lected in sterile containers before the initiation of therapy2 International Journal of Microbiology
Table 1: Stool specimens from malignant gastrointestinal diseases.
Malignant diseases Number of examined stool specimens
Carcinoma of the stomach 11
Carcinoma of the rectum 4
Carcinoma of the pancreas 7




Table 2: Stool specimens from non-malignant gastrointestinal dis-
eases.








testinal diseases in Ibn-Sina Specialized Hospital, Khartoum,
Sudan. The stool samples were from 28 inpatients with
malignant gastrointestinal diseases (Table 1), 27 inpatients
with non-malignant gastrointestinal diseases (Table 2), and
50 controls. All the patients and controls were men.
20 out of the 50 controls were outpatients who came
to the gastric intestinal tract clinic suﬀering from the
gastrointestinal tract problems and the medical examination
and laboratory tests showed that they did not have any type
of cancer.
The inpatients and the 20 controls were working in
agriculture and animal husbandry and aged between 25 and
65 years. 5% of each inpatients and controls aged from 25 to
50 years and 95% aged from 51 to 65 years.
30outofthe50controlswereapparently-healthyfarmers
aged 50–86 years and the mean age was 64 ± 10 years. They
had no history of taking any antimicrobial agent for at least
one month. The stool samples were collected during the
medical survey for infectious and tropical diseases organized
by University of Medical Sciences and Technology in Sudan
from Gezira agriculture Scheme with a population of 40
thousand people.
2.2. Culture of Stool Sample and Identiﬁcation of Growing
Bacteria. The stool samples were cultured on MacConkey
agar plates (Himedia Limited, Bombay) and incubated
aerobically at 37◦C overnight. Identiﬁcation of growing
bacteriawasperformedaccordingtostandardbacteriological
methods.
2.3. Susceptibility of Identiﬁed Bacteria to Antibiotics. Anti-
microbial susceptibility to penicillin and trimethoprim-sul-
famethoxazole was carried out on the isolated strains by disk
diﬀusion method on Mueller-Hinton agar plates (Himedia
Limited, Bombay). Sensitivity of bacteria to each antibiotic
was carried out by measuring the diameter of inhibition of
bacterial growth around the disc. A diameter of ≥26 mm
was considered as the cut-oﬀ point for sensitivity for the
penicillin and a diameter of ≥24 mm for the trimethoprim-
sulfamethoxazole according to National Committee for
Clinical Laboratory Standard (NCCLS) method.
2.4. Statistical Analysis. χ2 test was used for signiﬁcant prev-
alence of S. bovis in stool specimens from patients with ma-
lignant or with non-malignant gastrointestinal diseases.
The statistical analysis was also performed to compare





imens were collected from ﬁfty-ﬁve patients with malignant
and non-malignant gastrointestinal diseases and from ﬁfty
persons as control group. The specimens were examined to
the prevalence of Streptococcus bovis strains and their suscep-
tibility to the used antibiotics.
All the isolated S. bovis strains were found to be sensitive
topenicillinandtrimethoprim-sulfamethoxazolewithdiam-
eter of inhibition from 26 to 32mm and from 24 to 32mm,
respectively. S. bovis was not detected in the control group
but it was detected in the inpatients aged 51–65 years.
3.2. Prevalence of S. bovis in Malignant Gastrointestinal Dis-
eases. Bacteriological analysis of stool specimens from the
patientswithmalignantgastrointestinaldiseasesshowedthat
outof28specimensS.boviswasisolatedfrom10patients.Six
positive were from patients with carcinoma of the stomach,
and one positive was from each patient with carcinoma
of rectum, pancreas, colon, and liver. The prevalence of S.
bovis in stool from the patients with carcinoma in stomach,
rectum, pancreas, colon, polyps, and hepatocytes was 55%,
25%, 14%, 50%, 0%, and 50%, respectively (Table 3).
3.3. Prevalence of S. bovis in Nonmalignant Gastrointestinal
Diseases. Analysis of stool specimens from the patients with
non-malignant gastrointestinal diseases showed that out of
27 specimens S. bovis was isolated from 5 patients. Two
positive from patients with liver cirrhosis, two positive from
patientswithobstructivejaundice,andonefrompatientwith
portal hypertensionwerefound. Theprevalenceof S.bovis in
stool from the patients with Crohn’s disease, liver cirrhosis,
obstructive jaundice, portal hypertension, and viral hepatitis
was 0%, 28%, 33%, 14%, and 0%, respectively (Table 4).
3.4. Prevalence of S. bovis in Stool from the Patients with
Malignant and Nonmalignant Gastrointestinal Diseases and
Healthy Controls. From analysing the prevalence of S. bovis
instoolfromthepatientswithmalignantandnon-malignant
gastrointestinal diseases and healthy controls was 36%, 18%,
and 0%, respectively (Figure 1). The statistical analysisInternational Journal of Microbiology 3
Table 3: Prevalence of S. bovis isolated from patients with malignant gastrointestinal diseases.
Malignant Diseases Number of examined stool specimens Number of positive stool specimens Prevalence of S. bovis %
Carcinoma of the stomach 11 6 55
Carcinoma of the rectum 4 1 25
Carcinoma of the pancreas 7 1 14
Carcinoma of the colon 2 1 50
Pre-malignant Polyp 2 0 0
Hepatocellular carcinoma 2 1 50
Total 28 10 36
Table 4: Prevalence of S. bovis isolated from patients with non-malignant gastrointestinal diseases.
Non-malignant diseases Number of examined stool specimens Number of positive stool specimens Prevalence of S. bovis %
Crohn’s disease 4 0 0
Liver cirrhosis 7 2 28
Obstructive jaundice 6 2 33
Portal hypertension 7 1 14
Viral hepatitis 3 0 0


































Figure 1: Prevalence of S. bovis in stool from the patients with
malignant and non-malignant gastrointestinal diseases and healthy
controls.
showed that the prevalence of S. bovis in stool specimens
from patients with malignant or with non-malignant gas-
trointestinal diseases was statistically signiﬁcant (P value of
χ2 test was 0.02).
4. Discussion
Colorectal cancer is the fourth most common cancer among
men and third most common among women worldwide
[25]. It was reported that infectious agents accounted for
18% of all cancers worldwide [26]. S. bovis is Gram-positive
bacteriumcausingserioushumaninfections.Alargenumber




existence of S. bovis and malignant gastrointestinal diseases
since prevalence of the bacterium in stool from the patients
with carcinoma in stomach, rectum, colon, and hepatocytes
was 55%, 25%, 50%, and 50%, respectively. In comparison,
the prevalence of S. bovis in stool from the patients with
Crohn’s disease, liver cirrhosis, obstructive jaundice, portal
hypertension, and viral hepatitis was 0%, 28%, 33%, 14%,
and 0%, respectively.
From analysis the prevalence of S. bovis in stool from the
patients with malignant and non-malignant gastrointestinal
diseases and healthy controls was 36%, 18%, and 0%,
respectively. The χ2 test statistical analysis showed that the
prevalence of S. bovis in stool specimens from patients with
malignant or with non-malignant gastrointestinal diseases
was statistically signiﬁcant (P = 0.02). The current ﬁndings
conﬁrm the previous data that correlated the association of
S. bovis with colorectal cancer specially Klein study 1977 [17]
and the later studies [18–20].
In contrast to the literature regarding an association
with colorectal cancer, less is written about associations of
S. bovis with other gastrointestinal diseases or with other
cancers except Klein study 1977 [17] but Klein 1987 reported
also the lack of association of S. bovis with noncolonic
gastrointestinal carcinoma [27]. However, Alazmi et al., 2006
found that S. bovis bacteremia in adults was frequently
associated with hepatic dysfunction [28], and Zarkin et al.,
postulated a triad of S. bovis bacteremia, liver disease, and
colonic pathology whereby the liver disease might account
for the increased fecal carriage, entry to the portal venous
system, or passage from the portal to systemic circulation of
S. bovis [29].
Inthis context,ourﬁndings addmore informationabout
the association of S. bovis with non-malignant gastroin-
testinal diseases and with non-colonic cancer: since the
current study isolated S. bovis from the stool of patients4 International Journal of Microbiology
with liver cirrhosis, obstructive jaundice, and portal hyper-
tension (Table 4) and the bacterium was isolated from
stool of patients with carcinoma in stomach, rectum, and
hepatocytes (Table 3), the association of S. bovis with non-
malignant gastrointestinal diseases or with noncolonic can-
cer was not signiﬁcantly diﬀerent by χ2 test (P>0.05). How-
ever, Klein 1977 isolated S. bovis from stool of patients with
inﬂammatory bowel disease, other gastrointestinal disorders
and noncolonic neoplasms [17] and he found that presence
of S. bovis in stool of patients with non-colonic cancer was
not signiﬁcantly diﬀerent from that in controls [27].
Tjalsma and colleagues detected immune reactions
against S. bovis antigens in sera of 11 out of 12 colon cancer
patients and in 3 out of 4 patients with colon polyps. No
positive reaction was observed in 8 control subjects [30].
They found that one of the diagnostic antigens represents a
surface-exposed heparin-binding protein that, according to
their speculation, might be involved in the attachment of S.
bovis to tumor cells. They claim that proﬁling of the humoral
immune response against S. bovis infections may represent a
promising diagnostic tool in early detection of human colon
cancer. However, research has not yet determined if S. bovis
is a causative agent of colon cancer or if preexisting cancer
makes the lumen of the large intestine more hospitable to S.
bovis outgrowth [31].
Previous ﬁndings (reviewed in [31]) suggest an active
role of S. bovis in the promotion of intestinal carcinogenesis
when adult rats were treated with azoxymethane for 2 weeks
and subsequently received injections with either S. bovis
bacteria or wall-extracted antigens twice weekly. The authors
observed progression of preneoplastic lesions, enhanced
expression of proliferation markers, and increased produc-
tion of interleukin-8 in the colonic mucosa in these rats
[32]. The same group used a partially puriﬁed S. bovis S300
fraction representing 12 diﬀerent proteins and triggered the
synthesis of proinﬂammatory proteins (human interleukin-
8 and prostaglandin E2), correlated with the in vitro over-
expression of cyclooxygenase-2 in human colon carcinoma
cells and in rat colonic mucosa [33]. These data could point
to a role of oxygen radicals in colon carcinogenesis induced
by a chronic infection with S. bovis. The mechanism could
be similar to the one suspected for the development of
gastric carcinomas after persisting H. pylori infections since
a cecropin-like H. pylori peptide, Hp (2–20), was found to
be a monocyte chemoattractant and activated the monocyte
NADPH oxidase to produce oxygen radicals [34].
Presently it would still be important to know whether the
increased presence of S. bovis in colonic cancers and polyps
results from the preferential bacterial colonization of these
cancers and their precursors or whether S. bovis represents a
carcinogen that is causally involved in gastrointestinal cancer
[31]. However, our study presents a signiﬁcant association of
Streptococcus bovis with malignant gastrointestinal diseases.
5. Conclusions
The signiﬁcant association of S. bovis with malignant gas-
trointestinal diseases compared to its association with non-
malignant gastrointestinal diseases presented in this study
conﬁrms the previous studies about the association between
this bacterium and colorectal cancer and may support the
idea that there is correlation between this bacterium and the
malignant gastrointestinal diseases.
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